WuXi AppTec Co. Ltd. Sells 291,446 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)

WuXi AppTec Co. Ltd. reduced its position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 3.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,390,710 shares of the company’s stock after selling 291,446 shares during the quarter. Lyell Immunopharma comprises about 53.6% of WuXi AppTec Co. Ltd.’s portfolio, making the stock its biggest position. WuXi AppTec Co. Ltd.’s holdings in Lyell Immunopharma were worth $10,199,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of LYEL. GSA Capital Partners LLP increased its position in shares of Lyell Immunopharma by 1,285.5% during the third quarter. GSA Capital Partners LLP now owns 354,815 shares of the company’s stock worth $490,000 after acquiring an additional 329,205 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Lyell Immunopharma by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company’s stock valued at $68,000 after purchasing an additional 19,287 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in Lyell Immunopharma by 37.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 135,050 shares of the company’s stock worth $186,000 after purchasing an additional 36,715 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Lyell Immunopharma by 78.1% in the third quarter. SG Americas Securities LLC now owns 57,566 shares of the company’s stock worth $79,000 after purchasing an additional 25,247 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC raised its position in Lyell Immunopharma by 49.5% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 128,203 shares of the company’s stock valued at $186,000 after buying an additional 42,452 shares during the last quarter. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Stock Down 7.2 %

Shares of LYEL opened at $1.03 on Thursday. The stock has a 50 day moving average of $1.20 and a 200 day moving average of $1.65. Lyell Immunopharma, Inc. has a 12 month low of $0.85 and a 12 month high of $3.26.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.03. The firm had revenue of $0.03 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. Research analysts predict that Lyell Immunopharma, Inc. will post -0.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on LYEL shares. Bank of America downgraded shares of Lyell Immunopharma from a “buy” rating to an “underperform” rating and cut their price objective for the stock from $6.00 to $1.00 in a report on Wednesday, October 30th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a research report on Tuesday, November 12th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.